While HSBC maintains a 'buy' rating for Biocon it has cut its target price to Rs 390 from the earlier Rs 400 per share.

Vanguard Large-Cap Index Fund ETF Shares should perform well mid-term, but I expect near-term volatility; cautious optimism ...